Acadia Pharmaceuticals (ACAD) Non-Current Assets (2010 - 2026)

Acadia Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $509.2 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 94.79% year-over-year to $509.2 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 73.03% YoY), while the FY2025 annual figure was $502.1 million, up 101.29% from the prior year.
• Non-Current Assets was $509.2 million for Q1 2026 at Acadia Pharmaceuticals, up from $502.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $509.2 million in Q1 2026 to a low of $79.9 million in Q4 2022.
• Historically, Non-Current Assets has averaged $205.1 million across 5 years, with a median of $179.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets decreased 2.95% in 2022, then jumped 101.29% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $79.9 million in 2022, then surged by 66.3% to $132.8 million in 2023, then jumped by 87.79% to $249.4 million in 2024, then surged by 101.29% to $502.1 million in 2025, then gained by 1.42% to $509.2 million in 2026.
• The last three Non-Current Assets figures came in at $509.2 million (Q1 2026), $502.1 million (Q4 2025), and $254.3 million (Q3 2025), per Business Quant data.